SCHEDULE 13G/A 0001425738 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 06/30/2025 0001810182 ALX Oncology Holdings Inc. 00166B105 323 Allerton Avenue South San Francisco CA 94080 Rule 13d-1(c) Redmile Group, LLC DE 0.00 4641455.00 0.00 4641455.00 4641455.00 N 8.5 IA OO Redmile Group, LLC's beneficial ownership of the Issuer's common stock ("Common Stock") is comprised of (i) 3,391,455 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of certain warrants to purchase Common Stock (the "Warrants"), which, in each case, are owned by certain private investment vehicles managed by Redmile Group, LLC (collectively, the "Redmile Clients"), including Redmile Biopharma Investments III, L.P. ("RBI III"). The Common Stock and the Warrants may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on: (i) 53,444,020 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission on May 8, 2025 (the "Form 10-Q"); plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants. Jeremy C. Green X0 0.00 4641455.00 0.00 4641455.00 4641455.00 N 8.5 HC IN Jeremy C. Green's beneficial ownership of Common Stock is comprised of (i) 3,391,455 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants, which, in each case, are owned by the Redmile Clients, including RBI III. The Common Stock and the Warrants together may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on: (i) 53,444,020 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants. Redmile Biopharma Investments III, L.P. DE 0.00 3675481.00 0.00 3675481.00 3675481.00 N 6.7 PN RBI III may be deemed to beneficially own (i) 2,425,481 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. Percentage based on: (i) 53,444,020 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. ALX Oncology Holdings Inc. 323 Allerton Avenue, South San Francisco, CA, 94080 Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P. Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware Y Redmile Group, LLC - 4,641,455 (1) Jeremy C. Green - 4,641,455 (1) Redmile Biopharma Investments III, L.P. - 3,675,481 (2) Redmile Group, LLC - 8.5% (3) Jeremy C. Green - 8.5% (3) Redmile Biopharma Investments III, L.P. - 6.7% (3) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 4,641,455 (1) Jeremy C. Green - 4,641,455 (1) Redmile Biopharma Investments III, L.P. - 3,675,481 (2) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 4,641,455 (1) Jeremy C. Green - 4,641,455 (1) Redmile Biopharma Investments III, L.P. - 3,675,481 (2) (1) The shares of the Issuer's Common Stock reported herein are held by, or issuable upon exercise of the Warrants by, certain Redmile Clients, including RBI III, for which Redmile Group, LLC is the investment manager/adviser and, in such capacity, exercises voting and investment power over all of the shares of Common Stock held by the Redmile Clients and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the principal of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. (2) RBI III may be deemed to beneficially own (i) 2,425,481 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. (3) Percentage based on: (i) 53,444,020 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants. Y Y N See the response to Item 4. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Redmile Group, LLC /s/ Jeremy C. Green 08/14/2025 Jeremy C. Green /s/ Jeremy C. Green 08/14/2025 Redmile Biopharma Investments III, L.P. /s/ Jeremy C. Green 08/14/2025